Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
SAFE-LAAC CKD Trial has been designed to gather data on the most optimal strategy of
antiplatelet therapy after transcatheter left atrial appendage occlusion with Amplatzer or
WATCHMAN device in patients with the end-stage renal disease treated with chronic
haemodialysis or peritoneal dialysis